The present invention is directed to a method of treating a fungal infection comprising administering topically, to a subject in need thereof, an anti-fungal effective amount of roflumilast. Preferably, topically administered roflumilast is used to treat fungal infections, fungal growth of and/or hypersensitivity to the fungi Malassezia spp. Patients may also be suffering from seborrheic dermatitis, dandruff, dupilumab facial redness, Tinea versicolor, Pityriasis versicolor, Tinea circinata, Tinea pedis, Tinea unguium, Tinea manus, Tinea cruris, Tinea corporis, Tinea faciei, Tinea capitis, and/or Tinea incognito. Topically administered roflumilast is a quick and effective antifungal agent and presents a viable alternative to current antifungal treatments.

A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.

A method for inhibiting hair growth in mammals using compositions containing FP receptor antagonists (e.g., prostaglandin F analogs that are block activation of the FP receptor). The compositions can be applied topically to the skin and/or hair. The compositions can arrest hirsutism or hypertrichosis, reverse hirsutism and hypertrichosis, and further prevent hair growth. These compositions can also be used to protect hair from chemical or radiation-induced alopecia or hair loss. These compositions can also be used to inhibit pigmentation of the hair or skin.

Photochromic formulations including a core material and a photochromic layer overlying the core material and forming a particle are provided. The photochromic layer may include a plurality of photochromic materials, including a first photo-responsive pigment characterized by reversible diffuse reflectance at a first central wavelength from 490 nm to 520 nm in response to irradiation by photons of a first characteristic wavelength, a second photo-responsive pigment characterized by reversible diffuse reflectance at a second central wavelength from 570 nm to 590 nm in response to irradiation by photons of a second characteristic wavelength, and a third photo-responsive pigment characterized by reversible diffuse reflectance at a third central wavelength from 450 nm to 495 nm and a fourth central wavelength from 625 nm to 740 nm in response to irradiation by photons of a third characteristic wavelength. The first, second, and third characteristic wavelengths may be different.

A multi-chrome cosmetic hair composition is disclosed. The composition includes a base formula suitable for hair and an interference pigment providing a colored background exhibiting interference colors that are observable at different angles of observation. The formula is sufficient to enable a homogenous suspension of the interference pigment. The formula includes a propellant, denatured alcohol, neutralized octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4, a neutralizing agent sufficient to neutralize the octylacrylamide/acrylates/butylaminoethyl methacrylate copolymer 4 to a range of 80% to 100%, and a plasticizer. The interference pigment includes an opaque-type interference pigment consisting of particles ranging from 5 microns to 60 microns in size to fill in gaps on hair shaft surfaces and create a smooth, chrome-like effect on the hair. The interference pigment includes an inorganic layer that specularly reflects incident light and semi-transparent inorganic layers that refract the reflected light such that the interference colors are observable.

The invention provides novel compositions comprising semifluorinated alkanes and at least one compound sensitive or prone to oxidation. The compositions can be used as medicines that are topically administered to an eye or ophthalmic tissue. The invention further provides kits comprising such compositions.

The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

The present invention provides compounds and methods of use thereof for the treatment, prevention, and/or reduction of a risk of a disease, disorder, or condition in which aldehyde toxicity is implicated in the pathogenesis, including ocular disorders, skin disorders, conditions associated with injurious effects from blister agents, and autoimmune, inflammatory, neurological and cardiovascular diseases by the use of a primary amine to scavenge toxic aldehydes, such as MDA and HNE.

Disclosed are personal care formulations, personal care methods and personal care devices that comprise or use a gel, lotion, cream or the like comprising (a) one or more active ingredients for providing a beneficial effect to the skin and/or hair and/or mucous membranes of a human and (b) from about 1 percent by weight to about 50 percent by weight of foam forming component(s) comprising trans-1-chloro-3,3,3-trifluoropropene (1233zd(E).

Disclosed are personal care formulations, personal care methods and personal care devices that comprise or use a gel, lotion, cream or the like comprising (a) one or more active ingredients for providing a beneficial effect to the skin and/or hair and/or mucous membranes of a human and (b) from about 1 percent by weight to about 50 percent by weight of foam forming component(s) comprising trans-1-chloro-3,3,3-trifluoropropene (1233zd(E).